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Esophageal adenocarcinoma (EAC), with its precursor
lesion Barrett’s esophagus (BE), accounts for 2% of all
cancer-related deaths and has a very poor prognosis with
a median survival of less than one year. In addition, the
prevalence of BE is rapidly rising in the Western World,
resulting in a large number of individuals “at risk” for
this disease. However, a major limitation for defining this
risk population is the absence of reliable biomarkers,
which also affects the development of surveillance strate-
gies and chemoprevention therapies for BE and EAC.
The development of BE has been thought to arise largely
because of chronic esophageal inflammation and the sub-
sequent the expansion of some sort of an altered stem
cell population due to alteration of stromal niche factors.
This also leads to epigenetic alterations, which are com-
mon in cancer initiation and progression, such as
changes in DNA methylation. Many genes show great
promise as specific DNA methylation biomarkers, which
offer several advantages, as they are easy accessible in
body fluids such as blood, sputum, or urine and the DNA
containing the methylation information can be isolated
from formalin fixed paraffin embedded (FFPE) tissue as
well; the positive methylation signal can also be detected
in the presence of huge amounts of material from normal
cells giving a negative signal. We measured two DNA
methylation markers, DKK1 (a WNT antagonist, known
to be methylated in colorectal and gastric cancer which
has a function tumor cell niche formation) and TFAP2E
(a novel biomarker for nonresponse towards 5FU in
colon cancer) in a retrospective cohort of patients with
EAC collected at the Institute of Pathology at the TU
Munich (FFPE material), using Methylspecific-HRM-PCR
followed by pyrosequencing.
Results
In a cohort of 60 EAC patients (primary resections), DKK1
methylation was associated with overall survival (ROC
analysis, AUC 0.69, 95% CI, p < 0,001) as well as disease
free survival (AUC 0.63, 95% CI, p < 0,01). In another
cohort of 55 patients who received neoadjuvant che-
motherapy (5FU, cisplatin, folinic acid) TFAP2E methyla-
tion was found also to be associated with overall survival
(AUC 0.64, 95% CI, p < 0,05) but less so if patients who
did not receive 5FU (taxol, cisplatin) were included (AUC
0.62,95% CI, p < 0,05).
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